HomeCompareFMTX vs ORCC

FMTX vs ORCC: Dividend Comparison 2026

FMTX yields 10.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMTX wins by $17.3K in total portfolio value
10 years
FMTX
FMTX
● Live price
10.00%
Share price
$20.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.7K
Annual income
$1,873.10
Full FMTX calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — FMTX vs ORCC

📍 FMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMTXORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMTX + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMTX pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMTX
Annual income on $10K today (after 15% tax)
$849.58/yr
After 10yr DRIP, annual income (after tax)
$1,592.14/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, FMTX beats the other by $1,591.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMTX + ORCC for your $10,000?

FMTX: 50%ORCC: 50%
100% ORCC50/50100% FMTX
Portfolio after 10yr
$30.1K
Annual income
$937.07/yr
Blended yield
3.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

FMTX
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$20.00
-0.0% upside vs current
Range: $20.00 — $20.00
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMTX buys
0
ORCC buys
0
No recent congressional trades found for FMTX or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMTXORCC
Forward yield10.00%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$38.7K$21.4K
Annual income after 10y$1,873.10$1.04
Total dividends collected$14.3K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$20.00$16.00

Year-by-year: FMTX vs ORCC ($10,000, DRIP)

YearFMTX PortfolioFMTX Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$11,700$999.50$11,190$489.61+$510.00FMTX
2$13,611$1,092.86$12,229$256.01+$1.4KFMTX
3$15,752$1,188.27$13,216$130.74+$2.5KFMTX
4$18,140$1,285.22$14,207$66.02+$3.9KFMTX
5$20,793$1,383.22$15,234$33.17+$5.6KFMTX
6$23,731$1,481.79$16,317$16.62+$7.4KFMTX
7$26,972$1,580.48$17,468$8.32+$9.5KFMTX
8$30,539$1,678.86$18,695$4.16+$11.8KFMTX
9$34,453$1,776.52$20,006$2.08+$14.4KFMTX
10$38,738$1,873.10$21,407$1.04+$17.3KFMTX

FMTX vs ORCC: Complete Analysis 2026

FMTXStock

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Full FMTX Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this FMTX vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMTX vs SCHDFMTX vs JEPIFMTX vs OFMTX vs KOFMTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.